Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of Glax­o­SmithK­line’s Q2 up­date on Wednes­day, sci­ence chief Hal Bar­ron is mak­ing the rounds to talk up the phar­ma gi­ant’s late-stage strat­e­gy as the top ex­ecs con­tin­ue to woo back a deeply skep­ti­cal in­vestor group while push­ing through a whole new R&D cul­ture.

And that’s not easy, Bar­ron is quick to note. He told the Fi­nan­cial Times:

I think that cul­ture, to some ex­tent, is as hard, in fact even hard­er, than do­ing the sci­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER